1,4,7,8,11,14,17,20,21,21,29,32,33,36-TETRADECAAZAPENTACYLCLO-[12.12.1(6,9).1(19,22).1(31,34)]-HENTETRACONTA-6,9(41),19(40),21,31,34(39)-HEXAENE
Compound with spectra: 1 NMR
![1,4,7,8,11,14,17,20,21,21,29,32,33,36-TETRADECAAZAPENTACYLCLO-[12.12.1(6,9).1(19,22).1(31,34)]-HENTETRACONTA-6,9(41),19(40),21,31,34(39)-HEXAENE](/api/compound/aYzZWuDZtF.png?ph=true&h=300&w=458 "1,4,7,8,11,14,17,20,21,21,29,32,33,36-TETRADECAAZAPENTACYLCLO-[12.12.1(6,9).1(19,22).1(31,34)]-HENTETRACONTA-6,9(41),19(40),21,31,34(39)-HEXAENE")
| SpectraBase Compound ID | aYzZWuDZtF |
|---|---|
| InChI | InChI=1S/C27H48N14/c1-7-40-8-2-29-18-24-14-26(38-36-24)20-32-5-11-41(10-4-31-17-23-13-22(16-28-1)34-35-23)12-6-33-21-27-15-25(37-39-27)19-30-3-9-40/h13-15,28-33H,1-12,16-21H2,(H,34,35)(H,36,38)(H,37,39) |
| InChIKey | KSIGFNANQYWQCU-UHFFFAOYSA-N |
| Mol Weight | 568.8 g/mol |
| Molecular Formula | C27H48N14 |
| Exact Mass | 568.418638 g/mol |
| Copyright | Copyright © 2016-2024 W. Robien, Inst. of Org. Chem., Univ. of Vienna. All Rights Reserved. |
|---|---|
| Solvent | CD3OD |
3,6,9,12,13,16,19,22,25,26-DECAAZATRICYLCLO-[22.2.1.1(11,14)]-OCATCOSA-1(27),11,14(28),24-TETRAENE
3,9,12,13,16,22,25,26-OCTAAZATRICYCLO-[22.1.1(11,14)]-OCTACOSA-1(27),11,14(28),24-TETRAENE
VKTODYFCAZYKTE-UHFFFAOYSA-N
6,19-DIOXA-3,9,12,13,16,22,25,26-OCTAAZATRICYCLO-[22.2.1.1(11,14)]-OCTACOSA-1(27),11,14(28),24-TETRAENE
1-{2-{[(2-pyridyl)methyl]amino}ethyl}piperazine
N,N'-Bis-[2-(1-piperazinyl)-ethyl]-benzol-1,3-dimethanamine
N-(2-Piperazin-1-yl-ethyl)-isonicotinamidine
4-morpholineethanamine, N-[(4-methoxyphenyl)methyl]-
10-Benzyl-1,4-dioxa-7,10,13-triazacyclopentadecane
N-(2-Piperazin-1-yl-ethyl)-thiobenzamide
| Title | Journal or Book | Year |
|---|---|---|
| Dopamine Interaction in the Absence and in the Presence of Cu2+ Ions with Macrocyclic and Macrobicyclic Polyamines Containing Pyrazole Units. Crystal Structures of [Cu2(L1)(H2O)2](ClO4)4 and [Cu2(H-1L3)](ClO4)3·2H2O | Journal of the American Chemical Society | 2001 |